Secukinumab Open Label Roll-over Extension Protocol

Summary

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.

Timeline

Start

2020-12-22

Primary completion

2030-01-29

Completion

2030-04-04

Drugs

Indications